Skip to main content

Advertisement

SpringerLink
Log in

The Current Landscape of PARP Inhibitors in Ovarian Cancer

  • Gynecologic Oncology (A Fader, Section Editor)
  • Published:
Current Obstetrics and Gynecology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The aim of this study is to discuss the background of PARP inhibitors and to provide an overview of the utility of these drugs for treatment of epithelial ovarian cancer.

Recent Findings

Numerous phase I–III trials are presented within the manuscript that outline the safety and efficacy of several PARP inhibitors in women with primary and recurrent ovarian cancer. There are now three FDA-approved PARP inhibitors for use in ovarian cancer patients in the USA: olaparib, niraparib, and rucaparib. These drugs have activity both alone and in combination with other agents, including chemotherapy and targeted anti-cancer drugs. Although PARP inhibitor toxicities often overlap with chemotherapy including myelosuppression, fatigue, and gastrointestinal distress, there are idiosyncratic differences in adverse event profiles and peculiar aspects of each drug. Additionally, the indications for use differ with respect to line of chemotherapy, whether a germline or somatic BRCA mutation is required, and maintenance versus active treatment intention. Although these were initially thought to be only applicable to patients with germline BRCA mutations, we now know that other patients benefit from these agents alone and in combination.

Summary

The first PARP inhibitor was approved for use in the USA less than 3 years ago, but we are rapidly gaining knowledge about when and in which settings to use these drugs. Continued focused study with clinical trials will enable us to identify the optimal patient populations for prescription of these agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21. https://doi.org/10.1038/nature03445.

    Article  CAS  PubMed  Google Scholar 

  2. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell. 2010;39(1):8–24. https://doi.org/10.1016/j.molcel.2010.06.017.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–99. https://doi.org/10.1158/0008-5472.CAN-12-2753.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Pommier Y, O'Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8(362):362ps17. https://doi.org/10.1126/scitranslmed.aaf9246.

    Article  PubMed  Google Scholar 

  5. Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 2015;21(19):4257–61. https://doi.org/10.1158/1078-0432.CCR-15-0887.

    Article  CAS  PubMed  Google Scholar 

  6. [7/26/17]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10/news_detail_002196.jsp&mid=WC0b01ac058004d5c1.

  7. •• Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64. This phase 3 trial, NOVA, provided provocative data which precipitated the approval of niraparib in recurrent ovarian cancer patients with and without BRCA mutations.

    Article  CAS  PubMed  Google Scholar 

  8. Coleman RL et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949-61.

  9. •• Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–50. This basket trial of olaparib in patients with a germline BRCA mutation led to the approval of olaparib in 2014, the first FDA approved PARP inhibitor in the United States.

    Article  CAS  PubMed  Google Scholar 

  10. Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, et al. A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017.

  11. •• Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87. This phase 2 trial led to the approval of rucaparib in 2016 in patients with germline or somatic BRCA mutations and recurrent ovarian cancer.

    Article  CAS  PubMed  Google Scholar 

  12. Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, et al. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol. 2016;27(6):1013–9. https://doi.org/10.1093/annonc/mdw133.

    Article  CAS  PubMed  Google Scholar 

  13. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882–92. https://doi.org/10.1016/S1470-2045(13)70240-7.

    Article  CAS  PubMed  Google Scholar 

  14. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation—an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2015;137(3):386–91. https://doi.org/10.1016/j.ygyno.2015.03.042.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Scanlon SE, Glazer PM. Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. DNA repair. 2015;32:180–9. https://doi.org/10.1016/j.dnarep.2015.04.030.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Joyce F. Liu WTB, Michael J. Birrer, J-ML, Buckanovich RJ, Fleming GF et al. Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. ASCO 20172017.

  17. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207–14. https://doi.org/10.1016/S1470-2045(14)70391-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract. 2016;3(1):11. https://doi.org/10.1186/s40661-016-0033-6.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015;3(11):1257–68. https://doi.org/10.1158/2326-6066.CIR-15-0044.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Sarah Foster Adams OR, Lee J-H, McCance DJ, Westgate S, Eberhardt SC, Rutledge T, Muller C. Phase I study combining olaparib and tremelimumab for the treatment of women with BRCA-deficient recurrent ovarian cancer. ASCO 20172017.

  21. Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, et al. Safety and clinical activity of the programmed death-ligand 1 inhibitor Durvalumab in combination with poly (ADP-ribose) polymerase inhibitor Olaparib or vascular endothelial growth factor receptor 1-3 inhibitor Cediranib in women's cancers: a dose-escalation, phase I study. J Clin Oncol. 2017;35(19):2193–202. https://doi.org/10.1200/JCO.2016.72.1340.

    Article  PubMed  Google Scholar 

  22. Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017;28(3):512–8. https://doi.org/10.1093/annonc/mdw672.

    CAS  PubMed  Google Scholar 

  23. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21(13):2460–5. https://doi.org/10.1200/JCO.2003.07.013.

    Article  CAS  PubMed  Google Scholar 

  24. du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374–82. https://doi.org/10.1200/JCO.2014.55.7348.

    Article  PubMed  Google Scholar 

  25. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83. https://doi.org/10.1056/NEJMoa1104390.

    Article  CAS  PubMed  Google Scholar 

  26. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96. https://doi.org/10.1056/NEJMoa1103799.

    Article  CAS  PubMed  Google Scholar 

  27. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92. https://doi.org/10.1056/NEJMoa1105535.

    Article  CAS  PubMed  Google Scholar 

  28. Pujade-Lauraine E, Ledermann J, Penson R, et al. Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the Phase III SOLO2 Study. Presented at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO), March 12–15. National Harbor, Maryland. 2017.

  29. Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140(2):199–203. https://doi.org/10.1016/j.ygyno.2015.12.020.

    Article  CAS  PubMed  Google Scholar 

  30. Pujade-Laurainea JAL, Pensonc RT, Ozad AM, Korache J, Huzarskif T, Povedag A, Pignatah S, Friedlanderiand M, Colomboj N, editor. Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study Society of Gynecologic Oncology Annual Meeting; 2017 03/14/2017; National Harbor, MD.

  31. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med. 2010;362(20):1909–19. https://doi.org/10.1056/NEJMra0809889.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P, et al. Successes and challenges of PARP inhibitors in cancer therapy. Front Oncol. 2015;5:222.

    Article  PubMed  PubMed Central  Google Scholar 

  33. FDA. Summary Review for Regulatory Action. 2014.

  34. Bouwman P, Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res. 2014;20(3):540–7.

    Article  CAS  PubMed  Google Scholar 

  35. Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol. 2013;229(3):422–9. https://doi.org/10.1002/path.4140.

    Article  CAS  PubMed  Google Scholar 

  36. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451(7182):1116–20. https://doi.org/10.1038/nature06633.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008;68(8):2581–6. https://doi.org/10.1158/0008-5472.CAN-08-0088.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol. 2017;35(12):1274–80. https://doi.org/10.1200/JCO.2016.70.4627.

    Article  CAS  PubMed  Google Scholar 

  39. Dziadkowiec KN, Gasiorowska E, Nowak-Markwitz E, Jankowska A. PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Przeglad Menopauzalny Menopause Rev. 2016;15(4):215–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stephenson Cancer Center, Section of Gynecologic Oncology, The University of Oklahoma, 800 NE 10th Street, Oklahoma City, OK, 73104, USA

    Camille C. Gunderson, Megan E. Buechel & Kathleen N. Moore

  2. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Minnesota, 420 Delaware Street SE, MMC 395, Minneapolis, MN, 55455, USA

    Britt K. Erickson

Authors
  1. Camille C. Gunderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Britt K. Erickson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Megan E. Buechel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kathleen N. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Camille C. Gunderson.

Ethics declarations

Conflict of Interest

Britt K. Erickson and Megan E. Buechel declare no conflict of interest. Camille C. Gunderson is on the Clovis advisory board Dr Gunderson is also a consultant for Celsion. Kathleen N. Moore is on the advisory boards for Genentech Roche, Astra Zeneca, Amgen, Immunogen, Clovis, Tesaro, Janssen, and VBL Therapeutics.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Gynecologic Oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gunderson, C.C., Erickson, B.K., Buechel, M.E. et al. The Current Landscape of PARP Inhibitors in Ovarian Cancer. Curr Obstet Gynecol Rep 7, 20–27 (2018). https://doi.org/10.1007/s13669-018-0233-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13669-018-0233-7

Keywords

Search

Navigation